Novartis publishes Q3 impact and sustainability update
NVS•Novartis committed at least $250 million to global health R&D for 2026–2030, and the FDA granted Priority Review to antimalarial KLU156, shortening its evaluation period from 10 months to six months.
1. Health access and research
Novartis committed at least $250 million to global health research and development for 2026–2030. The FDA granted Priority Review to antimalarial KLU156, shortening its evaluation period from 10 months to six months. Phase II studies of oral leishmaniasis treatment LXE408 in India and Ethiopia concluded, with results scheduled for presentation on November 18, 2026.
2. Sustainability measures
Novartis retained first place in the 2026 Access to Medicine Index, ranking first across all three technical areas. Water consumption in its own operations fell 59% in 2025 versus 2016, and site-specific targets now cover prioritized operations in water-stressed basins.
